Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

137.52USD
18 Apr 2019
Change (% chg)

$-1.00 (-0.72%)
Prev Close
$138.52
Open
$139.40
Day's High
$140.24
Day's Low
$135.78
Volume
2,562,871
Avg. Vol
2,541,342
52-wk High
$148.97
52-wk Low
$118.62

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.66
Market Cap(Mil.): $366,184.41
Shares Outstanding(Mil.): 2,662.77
Dividend: 0.90
Yield (%): 2.62

Financials

  JNJ.N Industry Sector
P/E (TTM): 25.47 62.06 62.40
EPS (TTM): 5.40 -- --
ROI: -- 12.17 11.78
ROE: -- 13.11 12.61

UPDATE 1-Idorsia confirms 2019 spending plan as clinical trials "on track"

ZURICH, April 18 Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects.

18 Apr 2019

US STOCKS-Wall St edges higher on generally positive earnings

* Netflix, IBM dip in after-hours trading after posting earnings

17 Apr 2019

US STOCKS-Wall St edges higher on generally upbeat earnings

* Indexes up: Dow 0.14 pct, S&P 0.02 pct, Nasdaq 0.32 pct (Updates to late afternoon, changes dateline, byline)

17 Apr 2019

US STOCKS-Wall St inches higher on tech boost, Johnson & Johnson earnings

* Indexes up: Dow 0.17%, S&P 0.17%, Nasdaq 0.40% (Changes comment, updates prices)

16 Apr 2019

Pharmaceuticals drive J&J to better-than-expected quarterly profit

Johnson & Johnson on Tuesday reported a first-quarter profit that exceeded Wall Street expectations on higher sales of its prescription medicines, including a double-digit increase for its psoriasis treatment Stelara, even as the company faces fierce competition for some of its other important drugs.

16 Apr 2019

UPDATE 3-Pharmaceuticals drive J&J to better-than-expected quarterly profit

April 16 Johnson & Johnson on Tuesday reported a first-quarter profit that exceeded Wall Street expectations on higher sales of its prescription medicines, including a double-digit increase for its psoriasis treatment Stelara, even as the company faces fierce competition for some of its other important drugs.

16 Apr 2019

US STOCKS-Wall St rises on tech boost, robust Johnson & Johnson earnings

* Indexes up: Dow 0.40%, S&P 0.31%, Nasdaq 0.36% (Updates prices to open)

16 Apr 2019

US STOCKS SNAPSHOT-Wall St opens higher after upbeat UnitedHealth, J&J results

April 16 U.S. stocks opened higher on Tuesday, taking the S&P 500 to less than a percent away from an all-time high, after better-than-expected results from healthcare giants UnitedHealth and Johnson & Johnson.

16 Apr 2019

US STOCKS-Wall St set to open higher on robust healthcare earnings

* Futures up: Dow 0.66%, S&P 0.37%, Nasdaq 0.43% (Adds comment, updates prices)

16 Apr 2019

REFILE-Johnson & Johnson reports first-quarter sales above expectations

April 16 Johnson & Johnson reported first-quarter revenue above analysts' estimates on Tuesday, driven partly by demand for its Stelara treatment for psoriasis and Crohn's disease and cancer drugs Darzalex and Imbruvica.

16 Apr 2019

Earnings vs. Estimates